{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:49:07Z","timestamp":1784958547744,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Approximately 1140 people are diagnosed with polycythaemia vera (PV) annually in the United Kingdom (UK). Adherence to the British Society of Haematology (BSH) guidelines for PV diagnosis and management is not well understood. To explore UK\u2019s PV diagnosis, management practices and unmet needs. A structured survey, co-developed with a UK haematology consultant, an advanced nurse practitioner and a pharmacist, was completed by 57\/332 invited healthcare practitioners from July to October 2023 through 1:1 interviews conducted by Novartis Medical Science Liaisons. Results were analysed descriptively. Most respondents (68%) follow the BSH 2018 guidelines for diagnosing PV. Treatment goals are to reduce thromboembolic event risk and control haematocrit and symptoms. Most patients (68%) were receiving cytoreductive therapy (typically first-line hydroxycarbamide); 28% received antiplatelet medication and\/or venesection alone. Stable patients are usually monitored every 3 months through telephone (68%), increasing to monthly when uncontrolled, mainly in-person (54%). General practitioners (56%) manage cardiovascular risks, but there is doubt over referral response. All respondents monitor symptoms, with only 19% regularly using MPN10. The greatest educational need was identifying hydroxycarbamide resistance and intolerance (58%). This survey offers insights into therapeutic approaches and areas for improvement in the UK\u2019s PV clinical practice.<\/jats:p>","DOI":"10.1007\/s00277-025-06352-8","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:08:38Z","timestamp":1744175318000},"page":"1623-1631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring perceptions in the management and treatment of polycythaemia vera in the UK"],"prefix":"10.1007","volume":"104","author":[{"given":"Becky","family":"Bagnall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Woodley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozinder","family":"Bains","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"6352_CR1","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Barbui T (2023) Polycythemia Vera: 2024 update on diagnosis, risk stratification, and management. Am J Hematol 98:1465\u20131487. https:\/\/doi.org\/10.1002\/ajh.27002","journal-title":"Am J Hematol"},{"key":"6352_CR2","unstructured":"Haematological Malignancy Research Network (HMRN) Incidence. Accessed 29 January 2025. Available from: https:\/\/hmrn.org\/statistics\/incidence"},{"key":"6352_CR3","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia Vera: an international study. Leukemia 27:1874\u20131881. https:\/\/doi.org\/10.1038\/leu.2013.163","journal-title":"Leukemia"},{"key":"6352_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bjh.15648","volume":"184","author":"MF McMullin","year":"2019","unstructured":"McMullin MF, Harrison CN, Ali S et al (2019) A guideline for the diagnosis and management of polycythaemia Vera. A British society for haematology guideline. Br J Haematol 184:176\u2013191. https:\/\/doi.org\/10.1111\/bjh.15648","journal-title":"Br J Haematol"},{"key":"6352_CR5","doi-asserted-by":"publisher","unstructured":"Greenfield G, McMullin MF, Mills K (2021) Molecular pathogenesis of the myeloproliferative neoplasms. J Hematol Oncol 2021;14:103. https:\/\/doi.org\/10.1186\/s13045-021-01116-z","DOI":"10.1186\/s13045-021-01116-z"},{"key":"6352_CR6","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"6352_CR7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"6352_CR8","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36:1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"6352_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/bjh.15647","volume":"184","author":"MF McMullin","year":"2019","unstructured":"McMullin MF, Mead AJ, Ali S et al (2019) A guideline for the management of specific situations in polycythaemia Vera and secondary erythrocytosis: A British society for haematology guideline. Br J Haematol 184:161\u2013175. https:\/\/doi.org\/10.1111\/bjh.15647","journal-title":"Br J Haematol"},{"key":"6352_CR10","doi-asserted-by":"publisher","unstructured":"McMullin MF, Bareford D, Campbell P et al (2005) Guidelines for the diagnosis, investigation and management of polycythaemia\/erythrocytosis. Br J Haematol 130. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05535.x.:174\u2013\u200995","DOI":"10.1111\/j.1365-2141.2005.05535.x"},{"key":"6352_CR11","doi-asserted-by":"publisher","unstructured":"Loscocco GG, Mannelli F, Gugliemelli P et al Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA myeloproliferative neoplasms working party initiative. Am J Hematol 94:E239\u2013E242. https:\/\/doi.org\/10.1002\/ajh.25555","DOI":"10.1002\/ajh.25555"},{"key":"6352_CR12","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M et al (2022) Appropriate management of polycythaemia Vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol 9:e301\u2013e311. https:\/\/doi.org\/10.1016\/S2352-3026(22)00046-1","journal-title":"Lancet Haematol"},{"key":"6352_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/BLCTT.S409443","volume":"13","author":"A Duminuco","year":"2023","unstructured":"Duminuco A, Harrington P, Harrison C, Curto-Garcia N (2023) Polycythemia Vera: barriers to and strategies for optimal management. Blood Lymphat Cancer 13:77\u201390. https:\/\/doi.org\/10.2147\/BLCTT.S409443","journal-title":"Blood Lymphat Cancer"},{"key":"6352_CR14","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","volume":"96","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Koschmieder S, Foltz L et al (2017) The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol 96:1653\u20131665. https:\/\/doi.org\/10.1007\/s00277-017-3082-y","journal-title":"Ann Hematol"},{"key":"6352_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2147\/VHRM.S429995","volume":"19","author":"G Benevolo","year":"2023","unstructured":"Benevolo G, Marchetti A, Melchio R et al (2023) A. diagnosis and management of cardiovascular risk in patients with polycythemia Vera. Vasc Health Risk Manag 19:765\u2013778. https:\/\/doi.org\/10.2147\/VHRM.S429995","journal-title":"Vasc Health Risk Manag"},{"key":"6352_CR16","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1002\/hem3.143","volume":"8","author":"A Duminuco","year":"2024","unstructured":"Duminuco A, Au Yeung J, Vaghela R et al (2024) Development of a natural Language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms. HemaSphere 8:e143. https:\/\/doi.org\/10.1002\/hem3.143","journal-title":"HemaSphere"},{"key":"6352_CR17","unstructured":"NHS. NHS Health Check Available at: https:\/\/www.nhs.uk\/conditions\/nhs-health-check\/. Accessed 29 January 2025"},{"key":"6352_CR18","unstructured":"NHS England Network Contract Directed Enhanced Service. Cardiovascular disease prevention and diagnosis: supplementary guidance. Available at: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/09\/B0951-v-network-contract-des-20-21-cvd-supplementary-guidance.pdf. Accessed 29 January 2025"},{"key":"6352_CR19","doi-asserted-by":"publisher","unstructured":"Grunwald MR, Burke JM, Kuter D et al (2019) Symptom burden and blood counts in patients with polycythemia Vera in the united States: an analysis from the REVEAL study. Clin Lymphoma Myeloma Leuk 19. https:\/\/doi.org\/10.1016\/j.clml.2019.06.001.:579\u2013\u200984.e1","DOI":"10.1016\/j.clml.2019.06.001"},{"key":"6352_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1200\/JCO.2015.62.933","volume":"34","author":"H Geyer","year":"2015","unstructured":"Geyer H, Scherber R, Kosiorek H et al (2015) Symptomatic profiles of patients with polycythemia Vera: implications of inadequately controlled disease. J Clin Oncol 34:151\u2013159. https:\/\/doi.org\/10.1200\/JCO.2015.62.933","journal-title":"J Clin Oncol"},{"key":"6352_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.clml.2024.04.003","volume":"24","author":"AT Kuykendall","year":"2024","unstructured":"Kuykendall AT, Fine JT, Kremyanskaya M (2024) Contemporary challenges in polycythemia Vera management from the perspective of patients and physicians. Clin Lymphoma Myeloma 24:512\u2013522. https:\/\/doi.org\/10.1016\/j.clml.2024.04.003","journal-title":"Clin Lymphoma Myeloma"},{"key":"6352_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2147\/JBM.S189922","volume":"10","author":"D Cuthbert","year":"2019","unstructured":"Cuthbert D, Stein BL (2019) Polycythemia Vera-Associated complications: pathogenesis, clinical manifestations, and effects on outcomes. J Blood Med 10:359\u2013371. https:\/\/doi.org\/10.2147\/JBM.S189922","journal-title":"J Blood Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06352-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06352-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06352-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:10:49Z","timestamp":1745575849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06352-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6352"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06352-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided informed consent to participate in the survey. The survey did not require divulging of sensitive or patient-identifiable data. Ethics committee approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"BB has received honoraria for consultation from Novartis, Sandoz and Incyte. CW has received honoraria for consultation and speaker fees from Novartis and GSK.RB, AN and JR are all employees of Novartis Pharmaceuticals UK Ltd. KG is a former employee of Novartis Pharmaceuticals UK Ltd. MFM has received honoraria for speaking and advisory boards, travel accommodation and\/or expenses from Novartis, Bristol Myers Squibb, AbbVie, Incyte and GSK, and has received research funding from BMS and AOP.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}